Recognising neuropsychiatric involvement by systemic lupus erythematosus (SLE) is of
growing importance, however many barriers to this exist at multiple levels of our currently …

Systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), and Sjögren's
syndrome (SS) are heterogeneous autoimmune diseases. Severe manifestations and …

Objectives Previous studies have reported that a few inflammatory cytokines have
associations with systemic lupus erythematosus (SLE)—for example, IL-6, IL-17, and …

Background Targeting interleukin (IL)-6 has become a major therapeutic strategy in the
treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can …

Objective Platelets are mediators of inflammation with immune effector cell properties and
have been implicated in the pathogenesis of systemic lupus erythematosus (SLE). This …

Although tocilizumab treatment in severe and critical coronavirus disease 2019 (COVID-19)
patients has proven its efficacy at the clinical level, there is little evidence supporting the …

Stimulation of the inflammatory reflex (IR) is a promising strategy to treat systemic
inflammatory disorders. However, this strategy is hindered by the cost and side effects of …

Abstract Interleukin-6 (IL-6) is one of the cytokines implicated in murine and human SLE.
Only a few small studies have investigated IL-6 inhibition in human SLE. Currently, there are …

Autoantibodies to chromatin and dsDNA are a hallmark of systemic lupus erythematosus
(SLE). In a mouse model of monogenic human SLE caused by DNASE1L3 deficiency, the …

Lupus nephritis is a major cause of morbidity in patients with systemic lupus erythematosus.
Responsiveness to treatment is crucial to avoid chronic kidney disease. New molecules …